AI-generated · cited to primary sources · not investment advice
Cipla (500087) Nov 2025 Filing Analysis
Does management do what it says?
The chronic therapy mix in the Indian branded prescription business improved to 61.8% in Q2 FY26, surpassing the previous quarter's level. (3 exceeded across 3 tracked commitments)
“So I think if you look at it, the market grows at about 8% to 9% in the domestic formulation business. So I think we expect that to continue.”
Cipla successfully launched Afrezza, India's first and only inhaled rapid-acting insulin, during the quarter. (1 met across 1 tracked commitment)
“Agreement Type: Promotion and Distribution Product: Yurpeak (Tirzepatide) ... Target Market: India ... Distribution & Promotion Responsibility: Cipla”
Management confirmed they are maintaining the full-year EBITDA margin guidance of 23.5% to 24.5%. The Q1 FY26 actual EBITDA margin was 25.6%, which is currently tracking above the full-year target range. (1 met, 1 exceeded, 1 revised across 3 tracked commitments)
“And following a review of our other operations, we are revising our full year EBITDA margin guidance to about 22.75% to 24%. The earlier guidance was 23.5% to 24.5%.”
Management has increased R&D intensity to 7.1% of revenue in Q2 FY26, up from the 6.2% level in the previous quarter, reflecting an upgrade in investment commitment. (1 revised, 1 met across 2 tracked commitments)
“The R&D spend that we had planned for the year, so now that we are estimating the R&D spend for the entire year now as against the plan, what we had planned, the spend will be about 0.5% -- sorry, I may have said 500 basis points, I meant 50 basis points, 0.5% of revenue higher basically.”
The re-inspection of the Indore facility is still pending but expected to occur imminently. (1 in progress across 1 tracked commitment)
“We expect the reinspection of our Indore facility any time in this year and the early next.”
See the full cited Management analysis of Cipla
How durable is the business?
Cipla's scale moat is reinforced by its #1 ranking in the US Albuterol market and its status as the largest pharma company by volume in the Indian market. (1 expanding)
“Largest pharma company by Volume (units) in market”
See the full cited Business Model analysis of Cipla
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.